NCT04479631View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 12, 2020

Primary Completion Date

January 29, 2021

Study Completion Date

January 29, 2021

Conditions
COVID-19
Interventions
DRUG

BRII-196

BRII-196 given intravenously

DRUG

Placebo

Placebo given intravenously

Trial Locations (1)

Unknown

Investigative Site, Beijing

Sponsors
All Listed Sponsors
collaborator

TSB Therapeutics (Beijing) CO.LTD

INDUSTRY

lead

Brii Biosciences Limited

INDUSTRY

NCT04479631 - Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196 | Biotech Hunter | Biotech Hunter